Huayi Pharmaceutical Technology (Anhui) Co., Ltd.

To study the pharmacokinetic characteristics of a single oral dose of the test preparation (ibuprofen suspension, specification 100mL:2g, licensed by Dawei (Anhui) Pharmaceutical Co., Ltd.) and the reference preparation (ibuprofen suspension, specification 100mL:2g, trade name: Meilin, licensed by Shanghai Johnson Pharmaceutical Co., Ltd.) in healthy subjects under fasting and postprandial conditions, to compare the bioequivalence of the test preparation and the reference preparation, and to study the safety of the drug in healthy subjects

The pharmacokinetic characteristics of a single oral dose of the test preparation (Candesartan cilexetil tablets, specifications 8mg/12.5mg (each tablet contains 8mg candesartan cilexetil/12.5mg hydrochlorothiazide), licensed by Huayi Pharmaceutical Technology (Anhui) Co., Ltd.) and the reference preparation (Candesartan cilexetil tablets, specifications 8mg/12.5mg (each tablet contains 8mg candesartan cilexetil/12.5mg hydrochlorothiazide), trade name Blopress, licensed by CHEPLAPHARM Arzneimittel GmbH) in healthy subjects were studied, the bioequivalence of the test preparation and the reference preparation were compared, and the safety of the drug in healthy subjects was studied.

The pharmacokinetic characteristics of the test preparation (ebastine tablets, specification 10 mg, produced by Huayi Pharmaceutical Technology (Anhui) Co., Ltd.) and the reference preparation (ebastine tablets, specification 10 mg, trade name Kestine, certified by ALMIRALL, S.A.) were studied in healthy subjects after a single oral administration under fasting and fed conditions, the bioequivalence of the test preparation and the reference preparation was compared, and the safety of the drug in healthy subjects was studied.